Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
SELLAS Life Sciences Group, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
Prev close 11.27 · gapped above the open, then crossed back over prior close. High/low 11.86 at 4:00 am ET, 11.10 at 11:45 am ET.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“We provided GPS and Bristol-Myers Squibb provided nivolumab for this study.”
FILING10-K0001390478-26-000003cik 0001390478
“On March 31, 2022, we entered into an exclusive license agreement, or the GenFleet Agreement, with GenFleet Therapeutics (Shanghai), Inc., or GenFleet, a clinical-stage biotechnology company developing cutting-edge therapeutics in oncology and immunology, that grants rights to us for the development and commercialization of SLS009, a highly selective small molecule CDK9 inhibitor, across all therapeutic and diagnostic uses worldwide, except for Greater China.”
FILING10-K0001390478-26-000003cik 0001390478
“Our lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the WT1 protein, which is present in 20 or more cancer types.”
FILING10-K0001390478-26-000003cik 0001390478
“The experiment conducted and funded by the National Institute of Health, or NIH, through through the NCI Pediatric Preclinical in Vivo Testing, or PIVOT, program, included 27 patient-derived ALL tumors from pediatric patients.”
FILING10-K0001390478-26-000003cik 0001390478
“Given the potential immunobiologic and pharmacodynamic synergy between GPS and an immune check-point inhibitor (e.g., PD-1 inhibitor), we entered into a Clinical Trial Collaboration and Supply Agreement with Merck (known as MSD outside the United States and Canada), to assess the efficacy and safety of GPS in combination with Merck's anti-PD-1 therapy pembrolizumab with exploratory long-term follow-up for OS and safety.”
FILING10-K0001390478-26-000003cik 0001390478
“Under the agreement, 119 Table of Contents the IMPACT-AML network will conduct a clinical study evaluating SLS009, enabling access to multiple European clinical sites and patients.”
FILING10-K0001390478-26-000003cik 0001390478
“In December 2024, we announced that the pre-specified threshold of 60 events (deaths) per the protocol had been reached, triggering the interim analysis to be conducted by the Independent Data Monitoring Committee, or IDMC.”
FILING10-K0001390478-26-000003cik 0001390478
“Our sole CMO for GPS drug product is Lyophilization Services of New England, Inc. (PCI Pharma Services).”
FILING10-K0001390478-26-000003cik 0001390478
“Our sole CMO for GPS drug substance peptides is Polypeptide Group.”
FILING10-K0001390478-26-000003cik 0001390478
Watchlist prices, news filtered to it, and its next report on your desk.
SELLAS Life Sciences Group, Inc. has 9 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either SELLAS Life Sciences Group, Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of SELLAS Life Sciences Group, Inc.. Customers appear here when SELLAS Life Sciences Group, Inc. names them, or when a company names SELLAS Life Sciences Group, Inc. as a supplier in its own annual report.
SLS (SELLAS Life Sciences Group, Inc.) has 9 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.
Largest move on the map today: BMY −0.56%, in healthcare.